
Opinion|Videos|May 14, 2024
Applying NCCN Guidelines in the Treatment of mBC
Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy
2
The ABCs of Vitamin D Supplements: Exploring Their Health Benefits and Proper Use
3
FDA Approves Nerandomilast for Progressive Pulmonary Fibrosis
4
Occupational Factors Can Increase Risk of Long COVID
5





































































































































































































